• Sep 15, 2026

  $38.95+1.33%

  Comparable pharmaceutical companies moved +1.10% on average [1], and the stock's 1.33% gain was in line with that broader sector move [1].

  • 1Peer group

• Sep 14, 2026

  $38.44-0.57%

  Comparable pharmaceutical companies rose 2.00% on average [1], while the stock fell 0.57%, a move not shared with its peers [1], with trading volume at 2.1x its trailing average during the session [2].

  • 1Peer group
  • 2Market data

• Sep 11, 2026

  $38.66-2.25%

  GPCR fell 2.25% on the day, a move not shared by comparable pharmaceutical preparations companies, which averaged -0.18% with 3 of 5 falling and 2 rising [1].

  • 1Peer group

• Sep 10, 2026

  $39.55-4.07%

  Comparable pharmaceutical preparations companies fell -2.69% on average, with 4 of 5 declining [1]. The stock's -4.07% drop came alongside this broader group decline, though it exceeded the average move of its peers [1].

  • 1Peer group

• Sep 9, 2026

  $41.23+2.11%

  Structure Therapeutics discussed positive clinical data updates for its oral small molecule amylin and GLP-1 programs in chronic weight management [1]. Comparable pharmaceutical preparations companies fell 0.82% on average that day, meaning GPCR's 2.11% gain was not shared by that cohort [2]. Trading volume was 1.8 times the trailing average with a session range of 11.0% of the low [3].

  • 1Seeking Alpha
  • 2Peer group
  • 3Market data

• Sep 8, 2026

  $40.38-14.70%

  Structure Therapeutics shares fell after trial data for its lead obesity drugs were released [1]. Comparable pharmaceutical preparations companies also declined that day, down 2.63% on average, though the company's drop was steeper [2]. Volume was heavy at 4.7x the trailing average, with the stock trading across a 17.7% range of the day's low [3].

  • 1Seeking Alpha
  • 2Peer group
  • 3Market data

• Sep 4, 2026

  $47.34+0.00%

  Shares closed flat on the day [2], a move not shared by comparable pharmaceutical preparations companies, which rose 1.63% on average [1]. Trading volume was well below the trailing average, with the session confined to a narrow range [2].

  • 1Peer group
  • 2Market data

Closing prices for GPCR. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.